Evidence map›Paper›PMID 39487239›Full record

ArticleTechniques in coloproctology2024

Oncologic outcomes and trends in each colon cancer location and stages over the last two decades: insights from the SEER registry.

C Benlice, A H Elhan, M E Seker, E Gorgun, M A Kuzu

Abstract read
PubMed Publisher
In one paragraph

Article in Techniques in coloproctology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

C BenliceDepartment of General Surgery, School of Medicine, Ankara University, Sıhhıye, 06100, Ankara, Turkey. cigdembenlice@gmail.com.
A H ElhanDepartment of Biostatistics, Faculty of Medicine, Ankara University, Ankara, Turkey.
M E SekerSchool of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
E GorgunDepartment of Colorectal Surgery, DDSI, Cleveland Clinic, Cleveland, OH, USA.
M A KuzuDepartment of General Surgery, School of Medicine, Ankara University, Sıhhıye, 06100, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe main purpose of the study is to comprehensively evaluate population-level survival disparities stage-by-stage, according to specific anatomical colon segments, and based on prognosis as defined by lymph nodes among patients who have undergone curative resection for non-metastatic colon cancer.

methodsThe study was conducted from the Surveillance Epidemiology and End Result (SEER) program from the USA. Patients who underwent surgery for colon adenocarcinoma between 2000 and 2019 were identified. Demographics and clinical and pathologic factors were compared amongst each other according to different colon segments, stages, and time periods.

resultsA total of 482,672 patients were identified and 195,105 of them met the inclusion criteria. Patients with proximal cancers were significantly older, more likely to be female, had a higher number of lymph nodes, and node positivity (p < 0.001). During the study period, an almost 10% improvement in overall survival rate was observed at 3 and 5 years for each colon site and stage (p < 0.05).

conclusionsThe study's findings revealed a notable improvement in overall and cancer-specific survival rates across all colon segments and stages in patients who underwent curative treatment for non-metastatic primary colon cancer from a nationwide database.

Indexed as

AdenocarcinomaColonic NeoplasmsNeoplasm StagingSEER ProgramAdultAgedAged, 80 and overColonFemaleHumansLymphatic MetastasisLymph NodesMaleMiddle AgedPrognosisRegistriesColon cancerOverall and site-oriented survivalSEER data

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.